MAPT mutations in frontotemporal dementia and Alzheimer’s
The landscape of biomarkers for the management of Alzheimer's disease
The ideal patient for the U.S POINTER study
Where are our imaging techniques lacking?
Tau ligands and the future of Tau PET imaging